DSM signs Master Supply Agreement with Eisai Inc.

              DSM signs Master Supply Agreement with Eisai Inc.

PR Newswire

PARSIPPANY, N.J., March 5, 2013

PARSIPPANY, N.J., March 5, 2013 /PRNewswire/ --DSM Pharmaceutical Products,
the custom manufacturing and technology business of Royal DSM (NYSE/Euronext:
DSM KON), today announced the signing of a 3 year master supply agreement with
Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile
products. The agreement covers the production of eribulin mesylate as well as
other developmental drugs. Alexander Wessels, President and CEO of DSM
Pharmaceutical Products, stated, "We are delighted to be working with Eisai
under a long-term agreement to serve markets globally for important human
health treatments, bringing our expertise and reliability in sterile
injectables and worldwide regulatory record to ensure market supply."

DSM will be a supplier for eribulin mesylate to the US market. Commercial
production is anticipated to start in early 2013. Laura Parks, President, DSM
Pharmaceuticals, Inc., the finished dosage business of DSM, stated, "It has
been an honor to work with Eisai through the launch into commercial supply of
eribulin mesylate and to continue to support the development of other
products. Combining the expertise of Eisai in developing innovative medicines
with DSM's strength in Good Manufacturing Practices (GMP),  and supply chain
management will provide critical high quality treatments for patients."

DSM operates a 1.5 million square foot finished dosage facility in Greenville,
North Carolina, USA, with a broad range of capabilities in aseptic filling of
liquid and freeze-dried cytotoxic and non-cytotoxic steriles, the manufacture
of tablets and capsules, pharmaceutical development services, and clinical
trial materials manufacturing for solid and injectable forms, and holds a
range of regulatory approvals including the production of scheduled drugs.

Eisai is a research based human health care (hhc) company that discovers,
develops and markets products throughout the world. Through a global network
of research facilities, manufacturing sites and marketing subsidiaries, Eisai
actively participates in all aspects of the worldwide healthcare system.
"Eisai appreciates the focus and effort the DSM Pharmaceuticals team in
Greenville has provided in support of our commercial and developmental
products. We are particularly pleased to have received FDA approval to
manufacture eribulin mesylate at DSM for the commercial US market. This
alternate site of manufacturing strengthens the supply reliability of this
important product for our patients," added Shawn Gallagher, President
Partnership Management CFU, Eisai Inc.

No financial details were disclosed.

DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in Life Sciences and Materials
Sciences DSM is driving economic prosperity, environmental progress and social
advances to create sustainable value for all stakeholders. DSM delivers
innovative solutions that nourish, protect and improve performance in global
markets such as food and dietary supplements, personal care, feed,
pharmaceuticals, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based materials.
DSM's 23,500 employees deliver annual net sales of aroundEUR 9 billion. The
company is listed on NYSE Euronext. More information can be found at

For more information:

Guy Tiene                                      Laura Parks

Director, Marketing and Communications         President, DSM Pharmaceuticals,
tel. +1 973 257 8160
                                               tel. +1 252 707 7620
email guy.tiene@dsm.com
                                               email laura.parks@dsm.com

SOURCE DSM Pharmaceutical Products

Website: http://www.dsm.com
Press spacebar to pause and continue. Press esc to stop.